SUD-005 : epileptic seizures & pre-procedural anxiety

SUD-005 is a first-in-class strawberry/mint-flavoured oral spray formulation of midazolam (marketed in the USA as an injection or an oral syrup under the brand name Versed® by Roche) for the treatment of epileptic seizures and also pre-procedural anxiety in imaging and dental procedures.

Midazolam is one of the most frequently used agents for sedation in pediatric dentistry due to its potent anxiolytic, amnestic, hypnotic, anticonvulsant, skeletal muscle relaxant, and sedative properties. Midazolam has a fast recovery time and is the most commonly used benzodiazepine as a premedication for sedation.

Initial formulation work of SUD-005 has been completed and stability studies have been successful.

One major advantage of SUD-005 oral spray compared to an oral syrup or a tablet is the possible avoidance of first pass metabolism. This could offer other advantages such as an increase in the bioavailability of the drug, a reduction in dose variability; and more predictable pharmacological effects.

The market size for treatments of epileptic seizures and pre-procedural anxiety is estimated to exceed US$400 million

If you are interested to learn more about SUD-005 please email This email address is being protected from spambots. You need JavaScript enabled to view it. (Chief Business Officer).